Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aeglea BioTherapeutics, Inc. AGLE
$0.16
-$0 (-1.77%)
На 18:00, 12 мая 2023
+837.50%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
10587483.00000000
-
week52high
1.64
-
week52low
0.14
-
Revenue
2329000
-
P/E TTM
0
-
Beta
1.76124500
-
EPS
-0.99000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Equal-Weight | 09 авг 2022 г. |
| Needham | Hold | Buy | 03 июн 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 03 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Needham | Buy | Buy | 06 мая 2022 г. |
| Wells Fargo | Overweight | Equal-Weight | 28 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Goldberg Jeff Marc | A | 1884838 | 1884838 | 29 ноя 2022 г. |
| Neuman Linda L | A | 25000 | 25000 | 14 ноя 2022 г. |
| Souza Marcio | A | 90000 | 90000 | 25 авг 2022 г. |
| Kastenmayer James Paul | A | 130000 | 130000 | 23 авг 2022 г. |
| Alspaugh Jonathan | A | 130000 | 130000 | 23 авг 2022 г. |
| Hanley Jr. Michael Conick | A | 130000 | 130000 | 23 авг 2022 г. |
| Sloan Leslie | A | 130000 | 130000 | 23 авг 2022 г. |
| Hanley Jr. Michael Conick | A | 36200 | 28200 | 08 июн 2022 г. |
| Lawton Alison Frances | A | 43000 | 43000 | 07 июн 2022 г. |
| Shanafelt Armen | A | 43000 | 43000 | 07 июн 2022 г. |
Новостная лента
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:56
Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.
10 Top Penny Stocks To Watch Under $1
PennyStocks
25 апр 2023 г. в 12:52
Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
Seeking Alpha
24 апр 2023 г. в 22:42
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.
Penny Stocks to Buy Now? 7 Under $1 To Watch This Week
PennyStocks
24 апр 2023 г. в 10:52
Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?
3 Top Penny Stocks Under $1 To Watch Before Next Week
PennyStocks
21 апр 2023 г. в 13:18
Penny stocks to buy for under $1 but are they worth the risk? The post 3 Top Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.